Literature DB >> 9683971

Liver cirrhosis.

E J Williams1, J P Iredale.   

Abstract

Liver fibrosis and its related complications continue to represent a significant worldwide healthcare burden. Over the past decade there has been considerable improvement in our understanding of the cellular mechanisms and pathophysiology underlying hepatic fibrosis. This greater insight into the relevant basic sciences may lead to the development of novel treatment strategies designed to block the fibrogenic cascade or even enhance matrix degradation. In addition, there have been significant advances in the management of the complications of cirrhosis, with specific treatments now available for some conditions. Perhaps most notably, liver transplantation is now a highly successful treatment for end-stage liver disease and should be considered in all patients with chronic liver disease.

Entities:  

Mesh:

Year:  1998        PMID: 9683971      PMCID: PMC2360862          DOI: 10.1136/pgmj.74.870.193

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  42 in total

Review 1.  Rolling review: the treatment of major complications of cirrhosis.

Authors:  J Bosch; J Bruix; A Mas; M Navasa; J Rodés
Journal:  Aliment Pharmacol Ther       Date:  1994-12       Impact factor: 8.171

Review 2.  Matrix turnover in fibrogenesis.

Authors:  J P Iredale
Journal:  Hepatogastroenterology       Date:  1996 Jan-Feb

3.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  R P Perrillo; E R Schiff; G L Davis; H C Bodenheimer; K Lindsay; J Payne; J L Dienstag; C O'Brien; C Tamburro; I M Jacobson; R Sampliner; D Feit; J Lefkowitch; M Kuhns; C Meschievitz; B Sanghvi; J Albrecht; A Gibas
Journal:  N Engl J Med       Date:  1990-08-02       Impact factor: 91.245

4.  Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

Authors:  M Y Lai; J H Kao; P M Yang; J T Wang; P J Chen; K W Chan; J S Chu; D S Chen
Journal:  Gastroenterology       Date:  1996-11       Impact factor: 22.682

Review 5.  The treatment of chronic viral hepatitis.

Authors:  J H Hoofnagle; A M di Bisceglie
Journal:  N Engl J Med       Date:  1997-01-30       Impact factor: 91.245

Review 6.  Treatment of chronic hepatitis B with interferon: experience in western countries.

Authors:  R P Perrillo
Journal:  Semin Liver Dis       Date:  1989-11       Impact factor: 6.115

7.  Role of endoscopic variceal sclerotherapy in the long-term management of variceal bleeding: a meta-analysis.

Authors:  C Infante-Rivard; S Esnaola; J P Villeneuve
Journal:  Gastroenterology       Date:  1989-04       Impact factor: 22.682

Review 8.  Pathogenesis of liver fibrosis.

Authors:  R Alcolado; M J Arthur; J P Iredale
Journal:  Clin Sci (Lond)       Date:  1997-02       Impact factor: 6.124

9.  Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP)

Authors:  C Merkel; R Marin; E Enzo; C Donada; G Cavallarin; P Torboli; P Amodio; G Sebastianelli; D Sacerdoti; M Felder; C Mazzaro; P Beltrame; A Gatta
Journal:  Lancet       Date:  1996 Dec 21-28       Impact factor: 79.321

10.  Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group.

Authors:  H O Conn; N D Grace; J Bosch; R J Groszmann; J Rodés; S C Wright; D S Matloff; G Garcia-Tsao; R L Fisher; M Navasa
Journal:  Hepatology       Date:  1991-05       Impact factor: 17.425

View more
  10 in total

Review 1.  Telomere shortening as genetic risk factor of liver cirrhosis.

Authors:  Lucia Carulli
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

2.  In vivo effects of Chinese herbal recipe, Danshaohuaxian, on apoptosis and proliferation of hepatic stellate cells in hepatic fibrotic rats.

Authors:  Xiao-Xia Geng; Qin Yang; Ru-Jia Xie; Xin-Hua Luo; Bing Han; Li Ma; Cheng-Xiu Li; Ming-Liang Cheng
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

3.  Antisocial behavioral syndromes and past-year physical health among adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Risë B Goldstein; Deborah A Dawson; S Patricia Chou; W June Ruan; Tulshi D Saha; Roger P Pickering; Frederick S Stinson; Bridget F Grant
Journal:  J Clin Psychiatry       Date:  2008-03       Impact factor: 4.384

4.  Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis.

Authors:  R Sato; C Maesawa; K Fujisawa; K Wada; K Oikawa; Y Takikawa; K Suzuki; H Oikawa; K Ishikawa; T Masuda
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

5.  Hepatic 31P MRS in rat models of chronic liver disease: assessing the extent and progression of disease.

Authors:  I R Corbin; R Buist; J Peeling; M Zhang; J Uhanova; G Y Minuk
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

6.  A mouse strain where basal connective tissue growth factor gene expression can be switched from low to high.

Authors:  Heather E Doherty; Hyung-Suk Kim; Sylvia Hiller; Kathleen K Sulik; Nobuyo Maeda
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

7.  The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection.

Authors:  Huseyin Ataseven; Ibrahim Halil Bahcecioglu; Nalan Kuzu; Mehmet Yalniz; Selman Celebi; Ahmet Erensoy; Bilal Ustundag
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

8.  Assessment of serum acylated ghrelin in children and adolescents with chronic liver diseases: relation to nutritional status.

Authors:  Z A Elkabbany; R T Hamza; N H Mahmoud
Journal:  ScientificWorldJournal       Date:  2014-10-14

9.  Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis.

Authors:  Le Wang; Yuemin Feng; Xiaowen Ma; Guangchuan Wang; Hao Wu; Xiaoyu Xie; Chunqing Zhang; Qiang Zhu
Journal:  PLoS One       Date:  2017-08-18       Impact factor: 3.240

10.  Ascites of Unexplained Origin: A Case Report.

Authors:  Muteb A Alotaibi; Ahmad M Al Othman
Journal:  Cureus       Date:  2022-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.